Answers are grounded in this paper and cite their sources.
Review discusses efficacy and biological properties of PARP-targeted radionuclide therapy in cancer, suggesting future directions.
In recent years, numerous studies have investigated the use of poly (ADP-ribose) polymerase (PARP) inhibitors, labelled with various radionuclides, as agents for targeted radionuclide therapy. This review discusses current advances in studies with radiolabelled PARP inhibitors for targeted radionuclide therapy, focusing on radionuclide selection and (radio)biological properties. We highlight differences between radionuclides and their efficacy in killing cancer cells, while safeguarding healthy tissue. Furthermore, important biomarkers and dosimetry are explored, providing insights and future directions for advancing radiolabelled PARP inhibitors.
No takes yet. Share an insight, caveat, or question.
Kurniawan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: